Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy

 
• By Reed Miller

Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.

Neovasc Reducer
Neovasc Reducer • Source: Neovasc

More from Strategy

More from Business